A Single-Center, Open-Label Pilot Study Comparing De Novo Letermovir versus Valganciclovir for Cytomegalovirus Prophylaxis in African American Kidney Transplant Recipients (ATC 2026) - Jun 17, 2026 - Abstract #Abstract B386; Pres time: Jun 21, 2026; 02:45 PM - 03:45 PM; Location: Exhibit Hall; P3 | "This follow up results further confirms that LET is an effective, well-tolerated alternative to VGC for CMV prophylaxis in high-risk AA KTRs. LET was associated lower breakthrough CMV and leukopenia while maintaining comparable survival."
Clinical • Cytomegalovirus Infection • Hematological Disorders • Immunology • Infectious Disease • Leukopenia • Septic Shock • Transplant Rejection • Transplantation • CD4 • CD8 • CYP3A5
|
|
I. Yakubu; G. Abebe; D. Kumar; A. Brown; I. Moinuddin; M. Morales; S. Sterling; A. T. Iaria; B. Agegnehu; R. Marks; T. Sprague; M. Saeed; G. Gupta
|